Core Insights - Zomedica's mission focuses on delivering innovative diagnostic and therapeutic technologies to enhance pet care and improve pet parent satisfaction [1][2] - The company aims to streamline workflow, increase cash flow, and boost profitability for veterinary practices [1] Company Objectives - The first pillar is to improve the quality of care for pets [2] - The second pillar emphasizes enhancing pet parent satisfaction, ensuring confidence in the care provided [2] - The third pillar focuses on improving veterinarians' daily workflow for smoother operations [2] - The fourth pillar is committed to positively impacting veterinarian cash flow, making offerings financially accessible [2] - The fifth pillar aims to increase veterinarian profitability, providing solutions that help clinics grow financially [2]

Partnership Expected to Accelerate System Placements and Support Recurring Consumables Revenue Growth ANN ARBOR, MI / ACCESS Newswire / February 25, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative diagnostic and therapeutic products for equine and companion animals, today announced a commercial distribution agreement with Moichor, a recognized leader in veterinary reference and point-of-care laboratory services across the United States. Under t ...

Core Viewpoint - Zomedica is focusing on its R&D strategy to support scalable growth and enhance long-term shareholder value through an upcoming investor webinar [1] Group 1 - The company is an animal health firm that provides innovative diagnostic and therapeutic devices for both equine and companion animals [1] - The next installment of the "Fourth Friday at Four" investor webinar series is scheduled for February 27, 2026, at 4:00 p.m. Eastern Time [1]

Group 1 - The webinar is focused on Zomedica's technology innovation and aims to provide insights into the company's product platforms and the team driving its success [1][2] - The presentation includes forward-looking statements regarding future expectations, plans, and prospects, emphasizing the potential for actual results to differ [1][2] - The company expresses excitement about engaging with current and potential investors to enhance their understanding of the value delivered to veterinarians and shareholders [2] Group 2 - Larry Heaton, the Chief Executive Officer of Zomedica, is set to present during the webinar, indicating leadership involvement in communicating the company's vision [3]

Core Insights - The integration of advanced AI capabilities into Zomedica's TRUVIEW® AI digital microscopy system enhances diagnostic speed, consistency, and workflow efficiency for veterinary clinics [1] Company Developments - Zomedica Corp. has announced the incorporation of AI interpretation capabilities into its TRUVIEW® system, which will automate the interpretation of hematology blood films [1] - The company plans to extend the AI functionality to include skin and ear cytology in the near future [1]

Core Insights - Zomedica Corp. has entered into a contract manufacturing and service agreement with Rahm Sensor Development to produce the Cell-Guardian™, a personnel monitoring device aimed at enhancing safety in high-risk environments [1] Group 1: Agreement Details - The agreement allows Zomedica to leverage existing infrastructure to generate contract-based revenue [1] - It aims to improve asset utilization and support long-term cash flow [1] - The partnership is expected to create shareholder value through diversification into new markets [1] Group 2: Product Information - The Cell-Guardian™ is designed to provide advanced monitoring solutions for personnel in high-risk environments [1] - This product represents Rahm's first commercial offering in the market [1]

Core Viewpoint - Zomedica Corp. is enhancing its digital capabilities and long-term innovation strategy, as highlighted in its upcoming investor webinar scheduled for January 23, 2026 [1] Group 1 - Zomedica is an animal health company focused on innovative diagnostic and therapeutic devices for equine and companion animals [1] - The company will host the next session of its "Fourth Friday at Four" investor webinar series on January 23, 2026, at 4:00 p.m. Eastern Time [1]

Core Viewpoint - Zomedica Corp. has launched the VETGuardian PLUS monitor, enhancing its Zero Touch™ patient monitoring platform for veterinary clinics, aimed at improving workflow efficiency and clinical confidence while supporting long-term growth strategy [1] Group 1: Product Launch - The VETGuardian PLUS monitor is the next generation of the original VETGuardian® system [1] - New features have been added to improve ease of use and access to patient data [1] Group 2: Company Strategy - The launch of the VETGuardian PLUS monitor aligns with Zomedica's long-term growth strategy [1] - The product aims to strengthen clinical confidence in veterinary practices [1]

Core Insights - Zomedica Corp. is enhancing its commitment to pet wellness education through a collaboration with Prime Video, featuring its Assisi and Calmer Canine products in the movie Merv [1] Company Overview - Zomedica is an animal health company that provides innovative diagnostic and therapeutic devices for equine and companion animals [1] Industry Impact - The inclusion of Zomedica's technologies in a popular romantic comedy aims to raise awareness and educate the public about pet wellness [1]

Newest assay expands TRUFORMA market opportunity by building on endocrinology foundation to address reproductive health in the equine segment ANN ARBOR, MI / ACCESS Newswire / December 4, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced the expansion of its TRUFORMA platform with the launch of its equine progesterone assay, designed as a po ...